Bermele plc is a special purpose acquisition company formed to acquire realisable and/or developed commercial technologies or businesses.
The Company was formed for the purpose of acquiring a business or businesses operating in the pharmaceutical and biotechnology sectors. Further to the update to shareholders in February 2020, the Company has broadened its scope to review acquisition opportunities in all sectors.
The Directors continue to review a number of exciting opportunities, in order to deliver an exciting opportunity and significant value to shareholders. Further announcements will be made as appropriate.
The Acquisition, of either the assets, or the share capital, of a target company, will be treated as a Reverse Takeover and in order to maintain its listing the enlarged group would be required to apply to have its shares readmitted to the Official List and trading on the Main Market of the London Stock Exchange.